Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Combined Elevation Of Tumor Markers CA 19-9 And CA 125 In Liver Disease Patients Is Highly Specific For Severe Liver Fibrosis

M. Schöniger-Hekele, C. Müller
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Increased tumor markers in patients with liver cirrhosis are often considered to be unspecific. The use of this unspecific elevation to discriminate minimal fibrosis from severe fibrosis has never been explored. We aimed to answer the question, Do tumor markers predict severe liver fibrosis? The study group consisted of 125 patients with alcoholic liver disease, hepatitis B, or hepatitis C with available liver biopsy. Tumor markers CA 19-9, CA 15-3, and CA 125 were determined using routine laboratory methods and correlated with the extent of liver fibrosis. Fibrosis stages 1 and 2 were classified as minimal fibrosis; stages 3 and 4, as severe fibrosis.Tumor markers CA 19-9, CA 125, and CA 15-3 increased with stage of fibrosis. For separating patients with mild fibrosis (F1+F2) from patients with severe fibrosis (F3+F4), CA 19-9 had a sensitivity of 70.5% and a specificity of 88.6, CA 125 had 38.1% and 89.7%, and CA 15-3 had 19.0% and 93.0%, respectively. Logistic regression of a combined score of CA19-9 and CA 125 values revealed that an increase of 1 point of the CA 19-9/CA125 score resulted in a 1.6 times increase in likelihood of the presence of severe fibrosis. The CA 19-9/CA 125 score achieved a similar specificity (97.1% vs. 100%) but a higher sensitivity (42.9% vs. 33.3%) than the widely used cirrhosis discriminant score of Bonacini. A specificity (98.5%) similar to that of the CA 19-9/CA 125 score was reached by the easier determination of the combined elevation of CA 19-9 and CA 125, which had the best positive predictive value, 92.9%. The excellent predictive ability of the combined elevation of CA 19-9 and CA 125 for severe liver fibrosis (F3+F4) was confirmed in an independent group of patients with liver disease. The combined elevation of CA 19-9 and CA 125 is useful for identifying patients with advanced fibrosis or cirrhosis with high specificity. Patients without a combined elevation of CA 19-9 and CA 125 still require histological examination to identify severe fibrosis or cirrhosis.
This paper references
10.1016/0016-5085(91)70030-2
A simple biological index for detection of alcoholic liver disease in drinkers.
T. Poynard (1991)
10.1016/S0016-5107(82)73015-9
Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques--a review.
H. J. Nord (1982)
Serum tumor markers in chronic liver disease.
A. Kadayifci (1996)
10.1053/EJSO.1999.0925
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
D. V. Mann (2000)
10.1111/j.1572-0241.2001.05275.x
Predicting the liver histology in chronic hepatitis C: how good is the clinician?
J. Romagnuolo (2001)
10.1016/0140-6736(93)91946-J
Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis
J. Teare (1993)
10.1016/0168-8278(89)90592-8
PGA: A simple biological index for detection of alcoholic liver disease in drinkers
T. Poynard (1989)
10.1177/172460080001500304
Cholestasis is the Main Determinant of Abnormal CA 19–9 Levels in Patients with Liver Cirrhosis
E. Giannini (2000)
10.1016/0277-5379(88)90113-7
Tumor markers in non-malignant diseases.
Y. Touitou (1988)
10.1007/BF02087661
Alpha-2-macroglobulin and hepatic fibrosis
S. Naveau (2005)
Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients.
J. Collazos (1992)
10.1053/GAST.1997.V113.PM9352863
Noninvasive diagnosis of hepatic fibrosis or cirrhosis.
F. Oberti (1997)
10.1016/S0016-5085(00)86033-3
Validation of a discriminant score for the diagnosis of cirrhosis in patients with chronic hepatitis
Fadi N. Bashour (2000)
10.1016/S0168-8278(03)00005-9
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435].
V. Desmet (2003)
10.1046/j.1365-2893.2001.00314.x
Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor‐β
S. Kanzler (2001)
10.1053/JHEP.2001.20534
The role of liver biopsy in chronic hepatitis C
S. Saadeh (2001)
10.1002/HEP.1840010511
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
R. G. Knodell (1981)
10.1097/00007890-200111150-00008
ELEVATION OF CA-125 LEVEL IS DUE TO ABDOMINAL DISTENSION IN LIVER TRANSPLANTATION CANDIDATES
M. Deschenes (2001)
10.1177/172460089100600309
CA 15.3 in Nonmalignant Liver Diseases
J. Collazos (1991)
10.1155/1993/234238
The reliability of highly elevated CA 19-9 levels.
B. Osswald (1993)
10.1111/j.1572-0241.1999.01152.x
Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis
E. Zuckerman (1999)
10.1002/HEP.1840360720
The role of liver biopsy in chronic hepatitis C
J. Dienstag (2002)
10.7326/0003-4819-118-2-199301150-00013
Outpatient Liver Biopsy: How Safe Is It?
G. Garcia-Tsao (1993)
10.1016/S0168-8278(86)80075-7
Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.
F. Piccinino (1986)
10.1046/j.1365-2893.2001.00288.x
Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C
R. Myers (2001)
10.3109/02841869209083863
Breast cancer-associated antigen CA 15.3 in liver cirrhosis.
J. Collazos (1992)
19-9 in non-neoplastic liver diseases. A clinical and laboratory study
J Collazos (1992)
Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
M. Bonacini (1997)
10.1016/0009-8981(92)90053-S
CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.
J. Collazos (1992)
Histopathological diagnosis and terminology of chronic hepatitis.
J. Ludwig (1995)
10.1016/S0016-5085(98)70265-3
Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.
D. Guyader (1998)
10.1093/CLINCHEM/37.8.1379
Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases.
R. Molina (1991)
10.1002/HEP.510260710
The role of liver biopsy in hepatitis C
R. Perrillo (1997)
10.1038/bjc.1984.254
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
P. Canney (1984)



This paper is referenced by
10.3748/WJG.15.5976
Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.
W. Shen (2009)
10.1001/jama.2012.186
Does this patient with liver disease have cirrhosis?
J. Udell (2012)
10.1007/s00432-016-2248-7
Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer
Neveen A. Hussein (2016)
10.12816/EJHM.2018.16181
Comparative Study between Fibro-Test and Egy-Score as Non-Invasive Markers for Assessment of Hepatic Fibrosis in Chronic Hepatitis C
Fathy Ghamry Abd El razek Elghmary (2018)
10.2217/17520363.1.4.513
CA125 in ovarian cancer.
N. Scholler (2007)
10.1007/S13126-011-0040-3
Elevated levels of CA 19-9 and CA 125 in an amoebic cyst mimicking liver cancer
N. Kopanakis (2011)
10.5812/hepatmon.10810
Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study
M. Alboraie (2013)
Oncotargets and Therapy
Canturk Taşcı ()
10.5301/JBM.2012.9139
Elevation of CA 125 and CA 19–9 in patients with end-stage liver disease
A. Singhal (2012)
10.17795/ZJRMS959
The Frequency of CA15-3, CA125, CA19-9 in Patients With Hepatitis B and C
Somayeh Yeganeh-Amirkande (2015)
Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
M. Assmar (2016)
10.1155/2017/2416901
Mirrizi Syndrome and Markedly Elevated Levels of Carbohydrate Antigen 19-9 in the Absence of Malignant Disease
N. Shah (2017)
10.2217/14622416.7.5.759
The application of CD antigen proteomics to pharmacogenomics.
A. Woolfson (2006)
10.1111/j.1365-2710.2008.00995.x
Increased levels of CA 125 and CA 19·9 serum tumour markers following cyclic combined hormone replacement therapy
E. Cecchi (2009)
10.1016/j.dld.2008.04.002
Persistent elevation of serum CA 19-9 with no evidence of malignant disease.
M. Ventrucci (2009)
10.1136/bcr-2013-008979
Haemophagocytic lymphohistiocytosis presenting as liver failure following Epstein-Barr and prior hepatitis A infections
Gineth P. Pinto-Patarroyo (2013)
10.1155/2013/531640
Carbohydrate 19.9 Antigen Serum Levels in Liver Disease
G. Bertino (2013)
Hepa-index, a New Biomarker Indicator of Hepatic Fibrosis in Patients with Chronic Liver Disease
M. Alboraie (2012)
10.2147/OTT.S32888
The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis
C. Taşcı (2012)
10.1016/j.dld.2008.11.007
Abnormal serum tumour markers values do not imply the presence of extra-hepatic malignancies in patients with chronic liver disease.
C. Puoti (2010)
10.21608/AJPS.2015.12528
STUDY OF DES-GAMMA-CARBOXYPROTHROMBIN (DCP) LEVELS IN CHRONIC HEPATITIS C WITH OR WITHOUT HEPATOCELLULAR CARCINOMA (HCC) IN EGYPTIAN PATIENTS
Omnia Kamel (2015)
10.1016/j.dld.2008.12.094
How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?
B. Kim (2009)
10.1097/01.ELX.0000397025.95176.ca
Do serum CA 19-9 and CA 125 levels predict the severity of HCV-related liver fibrosis?
Mohammed Abd El-Hamid El-Bokl (2011)
10.1002/9781119188421.CH100
Tumor Markers in Pancreatic Malignancies
S. Hamada (2018)
10.1111/hepr.12385
Value of Egy‐Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase‐to‐platelet ratio index, FIB‐4 and Forns' index in chronic hepatitis C virus
M. Alboraie (2015)
10.1097/IPC.0B013E318181FA4D
Hemophagocytic Syndrome: Revisiting a Classic Diagnosis
Hortensia Álvarez Díaz (2008)
10.20344/AMP.5250
Two cases of the same family with the unusual elevation of CA19-9 levels.
M. Uyanik (2014)
10.1007/978-1-59745-188-8_14
The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease.
P. Ellmark (2008)
10.14218/JCTH.2017.00070
CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study
Raja Gr Edula (2018)
Semantic Scholar Logo Some data provided by SemanticScholar